Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Net Margin (2016 - 2025)

Northwest Biotherapeutics' Net Margin history spans 16 years, with the latest figure at 186.16% for Q4 2025.

  • Quarterly results put Net Margin at 186.16% for Q4 2025, up 1252209.0% from a year ago — trailing twelve months through Dec 2025 was 4461.32% (up 170308.0% YoY), and the annual figure for FY2025 was 4461.32%, up 170308.0%.
  • Net Margin for Q4 2025 was 186.16% at Northwest Biotherapeutics, up from 13591.0% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 186.16% in Q4 2025 to a low of 15947.57% in Q3 2022.
  • The 5-year median for Net Margin is 5228.8% (2025), against an average of 6090.77%.
  • The sharpest move saw Net Margin surged 289945337bps in 2021, then crashed -1220757bps in 2022.
  • Year by year, Net Margin stood at 3740.0% in 2021, then decreased by -27bps to 4740.03% in 2022, then soared by 32bps to 3217.53% in 2023, then plummeted by -283bps to 12335.93% in 2024, then surged by 102bps to 186.16% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 186.16%, 13591.0%, and 12166.41% for Q4 2025, Q3 2025, and Q2 2025 respectively.